Targeting epigenetic processes in photodynamic therapy-induced anticancer immunity

Frontiers in Oncology

Volumn 5, Issue JUL, 2015, Pages

  Wachowska, Malgorzata ^a   Muchowicz, Angelika ^a   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cancer; Epigenetic mechanisms; Histone deacetylase; Immunotherapy; Methyltransferase; Photodynamic therapy

Indexed keywords

CHEMOATTRACTANT; CYTOKINE; GROWTH FACTOR; TUMOR ANTIGEN;

ADAPTATION; ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; GENE EXPRESSION; GENETIC EPIGENESIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

EID: 84940109072     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00176     Document Type: Review

References (104)

1. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 61:250-81. doi: 10.3322/caac.20114.
2. Castano AP, Demidovaa TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther (2004) 1:279-93. doi:10.1016/S1572-1000(05)00007-4.
3. Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, Golab J. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol (2005) 52:339-52.
4. Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res (1985) 45:572-6.
5. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part three-photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther (2005) 2:91-106. doi:10.1016/S1572-1000(05)00060-8.
6. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 6:535-45. doi:10.1038/nrc1894.
7. Nowis D, Stoklosa T, Legat M, Issat T, Jakobisiak M, Golab J. The influence of photodynamic therapy on the immune response. Photodiagnosis Photodyn Ther (2005) 2:283-98. doi:10.1016/S1572-1000(05)00098-0.
8. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg Med (2006) 38:500-8. doi:10.1002/lsm.20337.
9. Firczuk M, Nowis D, Golab J. PDT-induced inflammatory and host responses. Photochem Photobiol Sci (2011) 10:653-63. doi:10.1039/c0pp00308e.
10. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer (2003) 3:380-7. doi:10.1038/nrc1071.
11. Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer (2003) 88:1772-9. doi:10.1038/sj.bjc.6600864.
12. Sun J, Cecic I, Parkins CS, Korbelik M. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Photochem Photobiol Sci (2002) 1:690-5. doi:10.1039/b204254a.
13. Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res (1996) 56:3281-6.
14. De Vree WJ, Essers MC, Koster JF, Sluiter W. Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. Cancer Res (1997) 57:2555-8.
15. Golab J, Wilczynski G, Zagozdzon R, Stoklosa T, Dabrowska A, Rybczynska J, et al. Potentiation of the anti-tumour effects of photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer (2000) 82:1485-91. doi:10.1054/bjoc.1999.1078.
16. De Vree WJ, Essers MC, De Bruijn HS, Star WM, Koster JF, Sluiter W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res (1996) 56:2908-11.
17. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett (1999) 137:91-8. doi:10.1016/S0304-3835(98)00349-8.
18. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer (1997) 75:202-7. doi:10.1038/bjc.1997.34.
19. Hendrzak-Henion JA, Knisely TL, Cincotta L, Cincotta E, Cincotta AH. Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy. Photochem Photobiol (1999) 69:575-81. doi:10.1111/j.1751-1097.1999.tb03330.x.
20. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2010) 1805:53-71. doi:10.1016/j.bbcan.2009.08.003.
21. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci (2011) 10:670-80. doi:10.1039/c0pp00294a.
22. Brackett CM, Gollnick SO. Photodynamic therapy enhancement of anti-tumor immunity. Photochem Photobiol Sci (2011) 10:649-52. doi:10.1039/c0pp00354a.
23. Schraml BU, Reis E, Sousa C. Defining dendritic cells. Curr Opin Immunol (2015) 32:13-20. doi:10.1016/j.coi.2014.11.001.
24. Jalili A, Makowski M, Switaj T, Nowis D, Wilczynski GM, Wilczek E, et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res (2004) 10:4498-508. doi:10.1158/1078-0432.CCR-04-0367.
25. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 31:1062-79. doi:10.1038/emboj.2011.497.
26. Gollnick SO, Owczarczak B, Maier P. Photodynamic therapy and anti-tumor immunity. Lasers Surg Med (2006) 38:509-15. doi:10.1002/lsm.20362.
27. Kushibiki T, Tajiri T, Tomioka Y, Awazu K. Photodynamic therapy induces interleukin secretion from dendritic cells. Int J Clin Exp Med (2010) 3:110-4.
28. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 12:265-77. doi:10.1038/nrc3258.
29. Mroz P, Hashmi JT, Huang YY, Lange N, Hamblin MR. Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 7:75-91. doi:10.1586/eci.10.81.
30. Daniels MA, Jameson SC. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med (2000) 191:335-46. doi:10.1084/jem.191.2.335.
31. Thong PS, Ong KW, Goh NS, Kho KW, Manivasager V, Bhuvaneswari R, et al. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol (2007) 8:950-2. doi:10.1016/S1470-2045(07)70318-2.
32. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets (2003) 4:525-36. doi:10.2174/1389450033490849.
33. Manjili MH. Revisiting cancer immunoediting by understanding cancer immune complexity. J Pathol (2011) 224:5-9. doi:10.1002/path.2865.
34. Seliger B. Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol (2008) 5:361-7. doi:10.1080/15476910802482870.
35. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol (2003) 195:346-55. doi:10.1002/jcp.10290.
36. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother (2004) 53:904-10. doi:10.1007/s00262-004-0517-9.
37. Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini JC, Romero P. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res (1997) 57:735-41.
38. Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P, et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol (2001) 31:2642-51. doi:10.1002/1521-4141(200109)31:9<2642::AID-IMMU2642>3.0.CO;2-6.
39. Sun Y, Sijts AJ, Song M, Janek K, Nussbaum AK, Kral S, et al. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res (2002) 62:2875-82.
40. Kontani K, Taguchi O, Narita T, Izawa M, Hiraiwa N, Zenita K, et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer (2001) 84:1258-64. doi:10.1054/bjoc.2000.1744.
41. Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, et al. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res (2003) 9:84-92.
42. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother (2006) 55:1159-84. doi:10.1007/s00262-006-0164-4.
43. Lettini AA, Guidoboni M, Fonsatti E, Anzalone L, Cortini E, Maio M. Epigenetic remodelling of DNA in cancer. Histol Histopathol (2007) 22:1413-24.
44. Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol (2006) 177:3100-7. doi:10.4049/jimmunol.177.5.3100.
45. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest (2006) 24:178-86. doi:10.1080/07357900500524579.
46. Wischhusen J, Waschbisch A, Wiendl H. Immune-refractory cancers and their little helpers-an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin Cancer Biol (2007) 17:459-68. doi:10.1016/j.semcancer.2007.07.005.
47. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419:734-8. doi:10.1038/nature01112.
48. Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med (2010) 16:98-105. doi:10.1038/nm.2074.
49. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res (1999) 5:2963-70.
50. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res (2007) 13:5262-70. doi:10.1158/1078-0432.CCR-07-1157.
51. Kawamura K, Bahar R, Natsume W, Sakiyama S, Tagawa M. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther (2002) 9:109-15. doi:10.1038/sj.cgt.7700418.
52. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 189:1363-72. doi:10.1084/jem.189.9.1363.
53. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ (2002) 9:1069-77. doi:10.1038/sj.cdd.4401073.
54. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 185:3190-8. doi:10.4049/jimmunol.0903670.
55. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol (1998) 161:3936-42.
56. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 19:5477-86. doi:10.1038/sj.onc.1203936.
57. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res (2001) 61:4942-6.
58. Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, et al. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res (2006) 12:3265-71. doi:10.1158/1078-0432.CCR-06-0076.
59. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol (2004) 16:157-62. doi:10.1016/j.coi.2004.01.010.
60. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 29:235-71. doi:10.1146/annurev-immunol-031210-101324.
61. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9:162-74. doi:10.1038/nri2506.
62. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol (2000) 165:779-85. doi:10.4049/jimmunol.165.2.779.
63. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol (2009) 182:240-9. doi:10.4049/jimmunol.182.1.240.
64. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 59:1593-600. doi:10.1007/s00262-010-0855-8.
65. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 64:5839-49. doi:10.1158/0008-5472.CAN-04-0465.
66. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 182:4499-506. doi:10.4049/jimmunol.0802740.
67. Momparler RL. Cancer epigenetics. Oncogene (2003) 22:6479-83. doi:10.1038/sj.onc.1206774.
68. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 22:50-5. doi:10.1016/j.gde.2012.02.008.
69. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 301:89-92. doi:10.1038/301089a0.
70. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet (2010) 70:27-56. doi:10.1016/B978-0-12-380866-0.60002-2.
71. Wanczyk M, Roszczenko K, Marcinkiewicz K, Bojarczuk K, Kowara M, Winiarska M. HDACi-going through the mechanisms. Front Biosci (Landmark Ed) (2011) 16:340-59. doi:10.2741/3691.
72. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 33(Suppl):245-54. doi:10.1038/ng1089.
73. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol (2003) 194:272-88. doi:10.1002/jcp.10215.
74. Mroz P, Vatansever F, Muchowicz A, Hamblin MR. Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res (2013) 73:6462-70. doi:10.1158/0008-5472.CAN-11-2572.
75. Van Den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med (1991) 173:1373-84. doi:10.1084/jem.173.6.1373.
76. Brandle D, Bilsborough J, Rulicke T, Uyttenhove C, Boon T, Van Den Eynde BJ. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol (1998) 28:4010-9. doi:10.1002/(SICI)1521-4141(199812)28:12<4010::AID-IMMU4010>3.0.CO;2-5.
77. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, et al. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 66:1105-13. doi:10.1158/0008-5472.CAN-05-3020.
78. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res (1994) 54:1766-71.
79. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, et al. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res (2002) 8:2690-5.
80. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 67:1781-90. doi:10.1002/pros.20665.
81. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 5:587-98.
82. Heninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 6:29. doi:10.3389/fimmu.2015.00029.
83. Sigalotti L, Fratta E, Coral S, Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther (2014) 142:339-50. doi:10.1016/j.pharmthera.2013.12.015.
84. Simova J, Pollakova V, Indrova M, Mikyskova R, Bieblova J, Stepanek I, et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. Br J Cancer (2011) 105:1533-41. doi:10.1038/bjc.2011.428.
85. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jager E, et al. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res (2010) 34:899-905. doi:10.1016/j.leukres.2010.02.004.
86. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol (2011) 86:918-22. doi:10.1002/ajh.22141.
87. Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, et al. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology (2008) 123:218-27. doi:10.1111/j.1365-2567.2007.02689.x.
88. Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res (2008) 68:9601-7. doi:10.1158/0008-5472.CAN-07-5270.
89. Gregorie CJ, Wiesen JL, Magner WJ, Lin AW, Tomasi TB. Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence. J Reprod Immunol (2009) 81:25-33. doi:10.1016/j.jri.2009.02.009.
90. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res (2013) 23(5):341-8. doi:10.1097/CMR.0b013e328364c0ed.
91. Chou SD, Khan AN, Magner WJ, Tomasi TB. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol (2005) 17:1483-94. doi:10.1093/intimm/dxh326.
92. Roulois D, Blanquart C, Panterne C, Gueugnon F, Gregoire M, Fonteneau JF. Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Eur J Immunol (2012) 42:783-9. doi:10.1002/eji.201141800.
93. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood (2008) 112:1424-33. doi:10.1182/blood-2008-01-133769.
94. Ballas ZK. The use of 5-azacytidine to establish constitutive interleukin 2-producing clones of the EL4 thymoma. J Immunol (1984) 133:7-9.
95. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood (2011) 117:2910-7. doi:10.1182/blood-2010-08-303701.
96. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, et al. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas-and NK cell-mediated cell death. Int J Oncol (2012) 41:83-91. doi:10.3892/ijo.2012.1438.
97. Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol (2012) 188:4441-9. doi:10.4049/jimmunol.1103035.
98. Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene (2009) 28:2370-82. doi:10.1038/onc.2009.117.
99. Chen WR, Liu H, Carubelli R, Nordquist RE. Synergistic effect of photothermal and photoimmunological reactions in treatment of metastatic tumors. J Xray Sci Technol (2002) 10:225-35.
100. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 61:192-6.
101. Castano AP, Liu Q, Hamblin MR. A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy. Br J Cancer (2006) 94:391-7. doi:10.1038/sj.bjc.6602953.
102. Mroz P, Szokalska A, Wu MX, Hamblin MR. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One (2010) 5:e15194. doi:10.1371/journal.pone.0015194.
103. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res (2009) 15:4460-6. doi:10.1158/1078-0432.CCR-09-0400.
104. Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, et al. 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer (2014) 50:1370-81. doi:10.1016/j.ejca.2014.01.017.